Weighing Trial Endpoints, PROs, and Treatment Logistics in mTNBC

The panel explores how to assign value to different trial endpoints in an aggressive disease, discussing overall survival as the gold standard while considering how crossover and confounding factors complicate its interpretation, and where PFS2 fits as a measure that reflects benefit across lines of therapy. Panelists discuss why progression-free survival may serve as a tighter surrogate in this setting given its shorter, more aggressive course. The conversation then shifts to the patient experience and practical logistics, including how dosing schedules, infusion times, and travel burden may influence treatment selection, particularly for younger patients balancing work and family. Panelists review patient-reported outcomes from the trials, including measures of quality-of-life preservation and time to deterioration, while noting which aspects of the treatment experience standard instruments may not fully capture. Viewers gain insight into weighing efficacy, endpoints, tolerability, and the lived patient experience together when individualizing care.